Ninety-nine per cent of people who experienced an immediate allergic reaction to their first COVID-19 shot tolerated a second dose without a severe response.
Patients struggling with chronic sinusitis and nasal polyps can greatly benefit from dupilumab, a biologic drug whose effectiveness was evaluated by researchers at McMaster.
Hamilton researchers have found that the inclusion of a third drug to commonly used dual-drug inhalers can reduce asthma exacerbations and improve control over the disease in children, adolescents, and adults with moderate-to-severe asthma.
McMaster logo
McMaster logo
